+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 40Years
All Genders
ID07778836

Evaluating Subcutaneous Nomlabofusp for Friedreichs Ataxia A Randomized, Placebo-Controlled Phase 3 Study

Led by Larimar Therapeutics, Inc. · Updated on 2026-10-09

150

Participants Needed

4

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of subcutaneous nomlabofusp in both adult and pediatric subjects with Friedreichs ataxia, a genetic condition. This is a global, randomized, multi-center, placebo-controlled Phase 3 study that aims to assess how nomlabofusp affects balance and overall disease severity compared to placebo over a period of 72 weeks. Participants will receive either a daily subcutaneous injection of nomlabofusp or a placebo for 72 weeks. The study includes two groups one receiving the active drug and the other receiving placebo injections. The study will measure changes in balance using the Upright Stability Score USS subscale E of the modified Friedreichs Ataxia Rating Scale mFARS and the total mFARS score, as well as the Clinical Global Impression of Severity CGI-S at multiple time points through Week 72. During the study, participants will undergo regular assessments at baseline and Weeks 12, 24, 36, 48, and 72. These evaluations include clinical scales measuring balance and disease severity. Safety and tolerability of nomlabofusp will also be monitored throughout. Participants must meet specific eligibility criteria including genetic confirmation of Friedreichs ataxia, performance on stability tests, and functional staging. The total duration of participation spans the 72-week treatment period with scheduled evaluations.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Research Team

L

Larimar Therapeutics, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here